Alkem laboratories has received a GST demand order from tax authorities, requiring the pharmaceutical company to pay ₹2.35 crores along with penalty and interest. The company disclosed this development to stock exchanges under Regulation 30 of SEBI listing regulations on January 22, 2026.

GST Demand Order Details

The order was issued by the Additional Commissioner, Central Goods & Services Tax, Goa, covering the assessment period from 2019-2020 to 2022-2023. The demand pertains to the company's Goa GSTIN operations during this four-year period.

Nature of Alleged Violation

The demand order primarily alleges excess availment of Input Tax Credit by the company during the specified period. The order has been issued under the applicable provisions of multiple GST legislations:

• IGST Act, 2017
• CGST Act, 2017
• SGST Act, 2017

The total financial implication includes the principal GST amount of ₹2.35 crores along with applicable interest and an equal penalty amount of ₹2.35 crores.

Company's Response and Legal Action

Alkem Laboratories has clearly stated its disagreement with the demand order and plans to contest the allegations. The company is preparing to take appropriate legal action, including filing an appeal against the order issued by the tax authorities.

The pharmaceutical company has emphasized that it does not agree with the findings in the demand order and will challenge the assessment through proper legal channels available under GST regulations.

Financial and Operational Impact

According to the company's disclosure, there is no material impact expected on its financial, operational, or other business activities from this GST demand order. This assessment suggests that the company views the order as contestable and expects to successfully challenge the allegations through the appeals process.

The disclosure was made pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulations, ensuring transparency with investors and stakeholders about this regulatory development.

Alkem Laboratories Limited has recorded a significant block trade on the National Stock Exchange (NSE), marking substantial institutional trading activity in the pharmaceutical company's shares. The transaction represents one of the notable bulk deals in the healthcare sector.

Block Trade Details

The block trade executed on NSE involved specific parameters that highlight the scale of the transaction:

Transaction Significance

Block trades represent large-scale transactions typically executed between institutional investors, mutual funds, or other significant market participants. These transactions are conducted outside the regular market mechanism to prevent substantial price impact on the stock during execution.

The transaction price of ₹5,856.00 per share reflects the market valuation at which the bulk transfer occurred. Such trades often indicate portfolio restructuring, institutional investment decisions, or strategic stake changes among large investors.

Market Impact

Block trades in pharmaceutical stocks like Alkem Laboratories often attract market attention due to their size and the involvement of institutional participants. The ₹15.32 crore transaction value demonstrates significant capital movement in the healthcare sector, reflecting continued investor interest in established pharmaceutical companies.